Adnavance Technologies is an early-stage developer of direct detection molecular diagnostic tests. The company's patented and ultra-sensitive metalized-DNA (M-DNAâ„¢) technology may eliminate the need for amplification for a large number of these tests. This technology provides many significant advantages over existing methods, including ease of use, time to result and cost. The platform is simple and inexpensive and is expected to receive FDA approval for use by any laboratory.
Funding Rounds (2) - $7.59MUpdate
|Aug 31, 2010||BioSpace - Adnavance Technologies raises 3850000 in venture round|
|Dec 18, 2009||adnavance.com - Adnavance Technologies raises 3738201 in venture round|
11494 Sorrento Valley Road, Suite H
San Diego, CA 92121